Somatostatin and the "Small-For-Size" Liver

Area of Science:

• Hepatology
• Surgical Gastroenterology
• Pharmacology

Background:

• Small-for-size (SFS) livers are susceptible to increased portal blood flow post-liver resection and transplantation.
• Excessive portal flow can overwhelm the liver, leading to failure and mortality.
• Somatostatin, a peptide hormone, can modulate portal flow and offer cellular protection.

Purpose of the Study:

• To review the challenges faced by SFS livers in the peri-operative period.
• To explore the potential benefits of somatostatin therapy in managing SFS livers.
• To highlight the role of somatostatin in mitigating risks associated with liver regeneration.

Main Methods:

• Literature review of studies on SFS liver physiology.
• Analysis of somatostatin's effects on portal hemodynamics.
• Examination of somatostatin's cytoprotective mechanisms in hepatic cells.

Main Results:

• SFS livers experience significant hemodynamic stress and regenerative demands.
• Exogenous somatostatin administration can effectively reduce portal blood flow.
• Somatostatin demonstrates protective effects on hepatocytes and other liver cells.

Conclusions:

• Peri-operative somatostatin therapy is a promising strategy for SFS liver management.
• Somatostatin can mitigate the risks of portal hyperperfusion and enhance liver recovery.
• Further clinical investigation is warranted to optimize somatostatin use in liver surgery.